Skip to main content

FDA & Regulatory

Complete Response Letter

A Complete Response Letter (CRL) is the FDA’s notice that it will not approve a drug in its current form, listing the deficiencies that must be resolved. A CRL is not a permanent rejection, but it typically delays approval by months to years and often triggers a sharp stock decline.

Category
FDA & Regulatory
Abbreviation
CRL
BioSniper AIPage evidence connected

Prepared research question

How does Complete Response Letter affect the view of a biotech company in practice?

Run cited research

Traceable citations · Unknowns marked

A Complete Response Letter (CRL) is the FDA’s notice that it will not approve a drug in its current form, listing the deficiencies that must be resolved. A CRL is not a permanent rejection, but it typically delays approval by months to years and often triggers a sharp stock decline.

Related terms

Learn more

From term to thesis rule

Investigate how Complete Response Letter changes a biotech thesis

Define when Complete Response Letter should count, block, or trigger a deeper check; BioSniper will compile that logic against available evidence.